Establishing the TSH reference intervals for healthy adults aged over 70 years: the Australian ASPREE cohort study.
Autor: | Tran C; School of Public Health and Preventive Medicine, 2541 Monash University , Melbourne, VIC, Australia., Topliss DJ; Department of Endocrinology and Diabetes, The Alfred Hospital, Melbourne, VIC, Australia.; School of Translational Medicine, Monash University, Melbourne, VIC, Australia., Schneider HG; School of Public Health and Preventive Medicine, 2541 Monash University , Melbourne, VIC, Australia.; Alfred Pathology Service, The Alfred Hospital, Melbourne, VIC, Australia., Seeman E; Department of Medicine and Endocrinology, Austin Health, Melbourne, VIC, Australia., Clayton-Chubb D; School of Translational Medicine, Monash University, Melbourne, VIC, Australia.; Department of Gastroenterology, The Alfred Hospital, Melbourne, VIC, Australia., Neumann JT; School of Public Health and Preventive Medicine, 2541 Monash University , Melbourne, VIC, Australia.; University Heart and Vascular Center Hamburg, University Medical Center Hamburg - Eppendorf, Hamburg, Germany.; German Center of Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lubeck, Hamburg, Germany., Kakoly N; School of Public Health and Preventive Medicine, 2541 Monash University , Melbourne, VIC, Australia.; Department of Public Health, North South University, Dhaka, Bangladesh., Zhou Z; School of Public Health and Preventive Medicine, 2541 Monash University , Melbourne, VIC, Australia., Hussain SM; School of Public Health and Preventive Medicine, 2541 Monash University , Melbourne, VIC, Australia.; Department of Medical Education, Melbourne Medical School, The University of Melbourne, Melbourne, VIC, Australia., Rickard AJ; School of Public Health and Preventive Medicine, 2541 Monash University , Melbourne, VIC, Australia., Clark DPQ; School of Public Health and Preventive Medicine, 2541 Monash University , Melbourne, VIC, Australia., Shah RC; Department of Family and Preventive Medicine and the Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA., Woods RL; School of Public Health and Preventive Medicine, 2541 Monash University , Melbourne, VIC, Australia., McNeil JJ; School of Public Health and Preventive Medicine, 2541 Monash University , Melbourne, VIC, Australia. |
---|---|
Jazyk: | angličtina |
Zdroj: | Clinical chemistry and laboratory medicine [Clin Chem Lab Med] 2024 Oct 03. Date of Electronic Publication: 2024 Oct 03. |
DOI: | 10.1515/cclm-2024-0848 |
Abstrakt: | Objectives: As thyroid disorders are common amongst the elderly, this study aims to evaluate the reference interval (RI) for thyroid stimulating hormone (TSH) in healthy adults aged 70 years and over. Methods: A proposed RI was determined from the Australian participants of the ASPirin in Reducing Events in the Elderly (ASPREE) randomised trial. Participants had no history of cardiovascular disease, thyroid cancer, dementia, or life-threatening illnesses. Participants prescribed with any thyroid-related medication at baseline were excluded. TSH levels were measured using a commercial chemiluminescence microparticle immunoassay. The RI was determined using the middle 95th percentile of the logarithmic transformed data of baseline TSH. Cox proportional hazard regression models were used to validate the RI by assessing disease incidence over time. Results: A total of 10,995 participants had baseline TSH measures. Median (IQR) age was 73.9 (71.8-77.3) years. We propose a RI of 0.34-3.75 mU/L. TSH levels did not differ by age or sex. At baseline, there was no association between symptoms associated with thyroid disease and levels of TSH. Over the follow-up period of up to 11 years, no association was seen between baseline TSH levels and relevant disease outcomes for participants within the RI. Conclusions: From a group of initially healthy, community-dwelling adults aged >=70 years, we propose a RI of TSH to best represent euthyroidism. This concentration was not associated with an increased risk of thyroid related symptoms or outcomes, confirming its appropriateness for clinical use. (© 2024 Walter de Gruyter GmbH, Berlin/Boston.) |
Databáze: | MEDLINE |
Externí odkaz: |